

## Aderans Research Treats One-Hundredth Subject in Clinical Study

*Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.*

Atlanta, GA ([PRWEB](#)) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based [hair regeneration](#), treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

“The breadth of this phase of our trial is tremendous,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on [pattern hair loss](#).”

Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months.

The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to [hair regeneration](#). During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth.

“This is leading edge research in our industry,” said Vern Liebmann, Vice President, Operations. “We’ve been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we’re collectively very excited to see the results beginning later this year.”

Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI's cellular regeneration techniques.

### About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world's largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI's study outcomes will be released as studies unfold. To see ARI's latest clinical updates, please visit [http://aderansresearch.com/ari\\_clinicalupdates.html](http://aderansresearch.com/ari_clinicalupdates.html)

Additional information on ARI can be found at [www.aderansresearch.com](http://www.aderansresearch.com).

Learn more about Aderans Co., Ltd. At <http://www.aderans.co.jp/e/company/>

**Contact Information****Vern Liebmann**

Aderans Research

<http://www.aderansresearch.com>

678.213.1913

**Online Web 2.0 Version**You can read the online version of this press release [here](#).**PRWebPodcast Available**[Listen to Podcast MP3](#) [Listen to Podcast iTunes](#) [Listen to Podcast OGG](#)